Hansa Biopharma AB (OSTO:HNSA)

kr 40.5 3 (8%) Market Cap: 2.66 Bil Enterprise Value: 3.06 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 77/100

Q3 2024 Hansa Biopharma AB Earnings Call Transcript
Oct 17, 2024

kr41.28 (+2.79%)

Earnings
Q2 2024 Hansa Biopharma AB Earnings Call Transcript
Jul 18, 2024

kr38.8 (-16.67%)

Earnings
Q1 2024 Hansa Biopharma AB Earnings Call Transcript
Apr 18, 2024

kr29.06 (-1.42%)

Earnings
Q4 2023 Hansa Biopharma AB Earnings Call Transcript
Feb 02, 2024

kr31.32 (-7.88%)

Earnings
Hansa Biopharma AB Carlsquare Life Science Investor Day Transcript
Dec 06, 2023
Q3 2023 Hansa Biopharma AB Earnings Call Transcript
Oct 26, 2023

kr24.42 (-12.28%)

Earnings
Q2 2023 Hansa Biopharma AB Earnings Call Transcript
Jul 20, 2023

kr45.06 (+1.49%)

Earnings
Q1 2023 Hansa Biopharma AB Earnings Call Transcript
Apr 20, 2023

kr45.66 (-11.68%)

Earnings
Hansa Biopharma AB at TD Cowen Health Care Conference Transcript
Mar 06, 2023
Q4 2022 Hansa Biopharma AB Earnings Call Transcript
Feb 02, 2023

kr53.5 (-12.94%)

Earnings
Nine months 2022 Hansa Biopharma AB Earnings Call Transcript
Oct 20, 2022

kr53.7 (-8.98%)

Earnings
Q2 2022 Hansa Biopharma AB Earnings Call Transcript
Jul 19, 2022

kr79 (+40.95%)

Earnings
Q1 2022 Hansa Biopharma AB Earnings Call Transcript
Apr 21, 2022

kr61.5 (+11.92%)

Earnings
Hansa Biopharma AB Erik Penser Bolagsdag Stockholm Transcript
Mar 10, 2022
Q4 2021 Hansa Biopharma AB Earnings Call Transcript
Feb 03, 2022

kr63.8 (-15.09%)

Earnings
Hansa Biopharma AB Deep Dive: Gene Therapy Hosted by HC Andersen Capital Transcript
Nov 05, 2021
Hansa Biopharma AB Redeye Interview Transcript
Oct 22, 2021
Q3 2021 Hansa Biopharma AB Earnings Call Transcript
Oct 21, 2021

kr109.1 (+0.41%)

Earnings
Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Q2 2021 Hansa Biopharma AB Earnings Call Transcript
Jul 15, 2021

kr114.2 (-17.19%)

Earnings
Hansa Biopharma AB Redeye Orphan Drugs Event - Corporate Call Transcript
Apr 28, 2021
Q1 2021 Hansa Biopharma AB Earnings Call Transcript
Apr 22, 2021

kr179.1 (+12.29%)

Earnings
Full Year 2020 Hansa Biopharma AB Earnings Call Transcript
Feb 04, 2021

kr181.5 (+0.55%)

Earnings
Hansa Biopharma AB at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Hansa Biopharma AB Corporate Analyst Meeting Transcript
Oct 29, 2020
Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 18, 2020
Half Year 2020 Hansa Biopharma AB Earnings Call Transcript
Jul 16, 2020

kr252 (-2.55%)

Earnings
Hansa Biopharma AB (publ) - Special Call Transcript
Jul 02, 2020
Hansa Biopharma AB at UBS Global Healthcare Conference (Virtual) Transcript
May 18, 2020
Q1 2020 Hansa Biopharma AB Earnings Call Transcript
Apr 28, 2020

kr121.1 (+5.49%)

Earnings
Q4 2019 Hansa Biopharma AB Earnings Call Transcript
Feb 06, 2020

kr70.15 (-5.39%)

Earnings
Hansa Biopharma AB (publ) - Special Call Transcript
Dec 13, 2019
Nine Months 2019 Hansa Biopharma AB Earnings Call Transcript
Oct 31, 2019

kr128.5 (-8.93%)

Earnings
Hansa Biopharma AB at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Q2 2019 Hansa Biopharma AB Earnings Call Transcript
Jul 18, 2019

kr172.9

Earnings
Hansa Biopharma AB at UBS Global Healthcare Conference Transcript
May 20, 2019
Q1 2019 Hansa Biopharma AB Earnings Call Transcript
Apr 29, 2019

Earnings

Q2 2024 Hansa Biopharma AB Earnings Call Transcript

Jul 18, 2024 / 12:00PM GMT

Release Date Price: kr38.8 (-16.67%)

Transcript

Operator

Hello, everyone, and welcome to the Hansa Biopharma Q2 2024 conference call. Today's call is being recorded. (Operator Instructions) I'll now hand the call over to CEO, Soren Tulstrup. Please begin.

Soeren Tulstrup

Hansa Biopharma AB - President, Chief Executive Officer

Thank you, operator. Good afternoon, good morning, and welcome, to the Hansa Biopharma conference call to review the first half and Q2 results for 2024. I'm Soren Tulstrup, President and CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; Matt Shaulis, Chief Commercial Officer and US President; Hitto Kaufmann, Chief R&D Officer. Please turn to slide 2.

These allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation and you should, therefore apply appropriate caution.

Please turn to slide 3 and an overview of today's agenda. They will discuss the progress we made during the first half of 2024 and review our near term authorities. The presentations should take roughly 15 to 20

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.